Regeneron Pharmaceuticals (REGN) Expected to Announce Earnings on Wednesday

Regeneron Pharmaceuticals (NASDAQ:REGN) is expected to be releasing its Q1 2026 results before the market opens on Wednesday, April 29th. Analysts expect the company to announce earnings of $9.10 per share and revenue of $3.4479 billion for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 8:30 AM ET.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. Regeneron Pharmaceuticals’s revenue was up 2.5% on a year-over-year basis. During the same quarter last year, the company posted $12.07 earnings per share. On average, analysts expect Regeneron Pharmaceuticals to post $35 EPS for the current fiscal year and $42 EPS for the next fiscal year.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $751.57 on Monday. Regeneron Pharmaceuticals has a 1 year low of $476.49 and a 1 year high of $821.11. The stock has a market capitalization of $79.46 billion, a price-to-earnings ratio of 18.08, a PEG ratio of 1.67 and a beta of 0.40. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. The stock’s fifty day moving average is $762.84 and its two-hundred day moving average is $733.31.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 5th. Investors of record on Friday, February 20th were paid a dividend of $0.94 per share. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.05%.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA approves Otarmeni (lunsotogene parvec-cwha), the first gene therapy to restore hearing — pivotal CHORD data showed ~80% met the primary endpoint and 42% achieved normal hearing on longer follow‑up, marking a breakthrough product and validating Regeneron’s genetic‑medicine efforts. Read More.
• Positive Sentiment: Analyst support: TD Cowen raised its price target to $960 (buy) and Cantor Fitzgerald reaffirmed an overweight rating with an $800 target — institutional upgrades can support upside as investors re‑rate growth prospects. Read More.
• Positive Sentiment: Regeneron reportedly secured tariff relief from the U.S. government for three years as part of the deal, which mitigates some cost headwinds and is a near‑term financial benefit. Read More.
• Neutral Sentiment: Regeneron will provide Otarmeni for free to eligible U.S. patients — a major access/PR move that increases uptake and public goodwill but has ambiguous near‑term revenue implications. Read More.
• Neutral Sentiment: Q1 preview / estimates: Research outlets (Zacks) are parsing Wall Street’s revenue and key‑metric estimates ahead of quarterly reporting — results will be important for near‑term stock direction. Read More.
• Neutral Sentiment: CEO Leonard Schleifer said Regeneron will provide Otarmeni for free in the U.S. but hasn’t decided on overseas pricing — international price strategy remains uncertain and will affect global revenue potential. Read More.
• Negative Sentiment: Drug‑pricing deal: Regeneron agreed to offer some prescriptions at “most‑favored‑nation” (MFN) prices and to lower U.S. drug costs under the administration deal — investors worry this could compress margins and reduce pricing power across the portfolio. Read More.

Wall Street Analyst Weigh In

Several equities research analysts have commented on REGN shares. Barclays started coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, March 6th. They issued an “overweight” rating and a $923.00 price target on the stock. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $818.00 to $801.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Oppenheimer reaffirmed an “outperform” rating and set a $865.00 target price (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Sanford C. Bernstein lowered their target price on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 8th. Finally, Piper Sandler initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 31st. They set an “overweight” rating and a $875.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $825.35.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.53, for a total transaction of $77,853.00. Following the sale, the director directly owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. The trade was a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Jason Pitofsky sold 2,036 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the sale, the senior vice president directly owned 4,272 shares in the company, valued at $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 3,774 shares of company stock worth $2,942,738 over the last three months. 7.02% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Insigneo Advisory Services LLC grew its holdings in shares of Regeneron Pharmaceuticals by 3.0% during the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 13 shares during the last quarter. Guardian Wealth Advisors LLC NC grew its holdings in shares of Regeneron Pharmaceuticals by 3.3% during the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock worth $342,000 after purchasing an additional 14 shares during the last quarter. Rexford Capital Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 5.5% during the fourth quarter. Rexford Capital Inc. now owns 288 shares of the biopharmaceutical company’s stock worth $222,000 after purchasing an additional 15 shares during the last quarter. Papamarkou Wellner Asset Management inc. grew its holdings in shares of Regeneron Pharmaceuticals by 4.7% during the fourth quarter. Papamarkou Wellner Asset Management inc. now owns 382 shares of the biopharmaceutical company’s stock worth $295,000 after purchasing an additional 17 shares during the last quarter. Finally, Meeder Advisory Services Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 1.7% during the fourth quarter. Meeder Advisory Services Inc. now owns 1,250 shares of the biopharmaceutical company’s stock worth $965,000 after purchasing an additional 21 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.